Bushen-Huoxue-Tonglin Formula on Benign Prostatic Hyperplasia in Rat Model of Ki-67 and Apoptotic Effects
10.11842/wst.2013.04.007
- VernacularTitle:补肾活血通淋方对良性前列腺增生症大鼠模型Ki-67及凋亡小体的影响
- Author:
Zixue SUN
;
Jianshe CHEN
;
Dong ZHOU
- Publication Type:Journal Article
- Keywords:
Bushen-Huoxue-Tonglin formula;
Ki-67;
apoptotic bodies;
benign prostatic hyperplasia
- From:
World Science and Technology-Modernization of Traditional Chinese Medicine
2013;(4):653-658
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to observe the effect of Bushen-Huoxue-Tonglin formula (BSHXTLF) on Ki-67 and apoptotic bodies in benign prostatic hyperplasia (BPH) rats. A total of 72 Wistar rats were randomly divided into 6 groups, which were the sham operation group, model group, Proscar group (0.8 mg?kg-1), BSHXTLF groups with low, middle and high dose (7.5, 15, 22.5 g?kg-1). Except the sham operation group, the BPH model was established by injecting testosterone propionate (5 mg?kg-1) for 30 days after removing both testicles in the rats. The drugs were administrated once a day for 30 days at the same time. The immunohistochemical and TUNEL methods were used to determine Ki-67 and apoptotic bodies, respectively. The results showed that compared with the model group , the expression of Ki-67 in treatment groups was decreased ( P < 0 . 05 ) . Compared with Proscar group and low-dose BSHXTLF group, the expression of Ki-67 in the middle- and high-dose BSHXTLF group was decreased ( P < 0 . 05 ) . Compared with the middle-dose BSHXTLF group , the expression of Ki-67 in the high-dose BSHXTLF group was decreased ( P < 0 . 05 ) . Compared with the model group , the expression of apoptot-ic bodies in each treatment group was increased ( P < 0 . 05 ) . Compared with Proscar group , low-dose and middle-dose BSHXTLF group, the expression of apoptotic bodies in the high-dose BSHXTLF group was increased (P <0.05). It was concluded that BSHXTLF may decrease the expression of Ki-67 and increase the expression of apoptotic bodies in BPH rats. These results provided objective evidences for clinical treatment of BPH.